
In this episode, your host, Henry Norton, is joined by Hannah Claridge, the Head of Neurotechnology at TTP, to talk about the incredible advancements that are being made to treat neurological conditions.
Hannah points out how complex the brain and nervous systems are, with both relying on intricate connections. She also explores the new technologies that are being developed to treat nervous disorders, such as spinal cord stimulation.
She also compared neurotechnologies to pharmaceuticals, highlighting the parallels and differences in how they interact with the body.
Hannah also suggested that neurotherapy will be key to the advancement of treatments for conditions like depression, due to their ability to provide targeted and long-term relief of symptoms.
Cybersecurity is also a major concern for neurotechnology, as any malfunction or deliberate interference could have serious ramifications for patients.
Key Topics:
Hannah’s current role at TTP
Recent innovations in neurotechnology
Policy and ethics in neurotech
Barriers to market adoption
Moving patient stories
Related Insights:
Humans use far more than 10% of the brain - this was debunked during a conversation about brain plasticity
There are significant barriers to market adoption for neurosurgery, such as a lack of awareness and understanding, even among surgeons.
Neurotech’s impact on patients cannot be understated, as so many conditions are currently untreatable with other intervention methods.
Core Challenges:
Anything that interacts with the brain in a way that changes its fundamental functions comes with huge ethical concerns and a need for heightened patient understanding and clear consent.
Neurotechnology can provide relief for chronic conditions, such as long-term pain relief and the alleviation of depressive symptoms, making it a game-changing device in several areas.
The challenges when it comes to developing a new neurotech product from being intuitive to miniaturisation.
Tune in now to find out how neurotechnology will change healthcare for the better.